Congratulations! You have successfully advanced your drug candidate to the point where it is ready for out-licensing (or so you believe, anyway). You believe that now is the time to…
Why don't companies write business plans anymore? Are they useless? Is it simply faster to put together 10 slides? In this post, we discuss this interesting question.
https://youtu.be/nXkNQpLNz-M We recently completed a Scouting project on behalf of a geographically-focused company. In this video, we discuss some of the lessons learned. We also provide some suggestions for addressing…
Still working on that wave? Like many of you, I am also knee-deep in last minute preparations for BIO. For many of us, this will be the first live partnering…
Easier said than done... Consider the following scenario… You are the CEO of an emerging biotech company. You have managed to raise enough capital to advance a small molecule through…
…the enduring competitive advantages in a global economy lie increasingly in local things – knowledge, relationships, motivation – that distant rivals cannot match. When Michael Porter wrote this in 1998,…
As our current situation continues to evolve, it is critical that your out-licensing and/or financing business plans and presentations account for COVID-19. This should be communicated to prospective investors and…
Empty spaces. What are we living for? Abandoned places. I guess we know the score... Over the past few months, our industry has been thrust in a variety of different…
Will the current coronavirus situation affect biotech and pharma business development?Yes...and No. As with most things, the answer depends on your point of view, the market you happen to be in,…
Ophthalmology is changing. If we look back 5-10 years, topical formulations of novel or established drugs were the norm in ophthalmology product development. These days, we are seeing antisense, gene…